单纯疱疹病毒治疗市场（依药物类型、给药途径及地区）

单纯疱疹病毒治疗市场规模预计在 2025 年为 26.536 亿美元，预计到 2032 年将达到 39.117 亿美元，2025 年至 2032 年的复合年增长率为 5.7%。

单纯疱疹病毒 (HSV) 是一种会导致生殖器疱疹和口唇疱疹的病毒感染疾病。它是一种感染疾病极强的病毒。 HSV 有两种类型：HSV-1 和 HSV-2。生殖器疱疹无法治愈，但每日服用抗病毒药物可以预防或缩短疱疹发作。因此，全球对安全有效的单纯疱疹病毒治疗的需求日益增长。

市场动态：

单纯疱疹病毒感染疾病盛行率的增加、临床试验数量的增加、对安全有效的 HSV 治疗的需求不断增长以及人们对单纯疱疹病毒认识的提高是预计在预测期内促进全球单纯疱疹病毒治疗市场增长的关键因素。

例如，2021年10月，联合生物製药、上海市公共卫生临床中心和上海中大微生物学系合作，研究了首创长效药物UB-621治疗由单纯疱疹病毒1型和2型（HSV 1和2）引起的生殖器疱疹的疗效。此外，世界卫生组织（WHO）及其合作伙伴正在支持进行研究，以开发预防和控制单纯疱疹病毒感染的新策略。

本研究的主要特点

• 本报告对全球单纯疱疹病毒治疗市场进行了详细分析，并提供了预测期 2025-2032 的市场规模和年复合成长率(CAGR)，以 2024 年为基准年。
• 它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
• 该报告涵盖了全球单纯疱疹病毒治疗市场的主要企业概况，基于以下参数，例如公司亮点、产品系列、关键亮点、财务绩效和策略。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球单纯疱疹病毒治疗市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
• 相关人员可以透过用于分析全球单纯疱疹病毒治疗市场的各种策略矩阵来更轻鬆地做出决策。

目录：

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 单纯疱疹病毒感染率上升
  • 围绕性行为感染传染病（STD）的社会耻辱
  • 对安全有效的 HSV 治疗的需求不断增加
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

4. 2020 年至 2032 年全球单纯疱疹病毒治疗市场（按药物）

• 阿昔洛韦
• 伐昔洛韦
• 泛昔洛韦
• 其他药物

5. 2020 年至 2032 年按给药途径分類的全球单纯疱疹病毒治疗市场

• 口服
• 注射
• 外用

6. 2020 年至 2032 年全球单纯疱疹病毒治疗市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲

第七章 竞争态势

• Fresenius SE & Co. KgaA
• Glenmark Pharmaceuticals
• Carlsbad Tech
• GlaxoSmithKline PLC
• Zydus Cadila
• Epi Health LLC
• Viatris Inc.
• Apotex Inc.
• Teva Pharmaceuticals Industries Ltd.
• Emcure Pharmaceuticals Ltd（Avet Pharmaceuticals Inc.）

第 8 章 章节

• 调查方法
• 关于出版商

Herpes Simplex Virus Treatment Market size is estimated to be valued at USD 2,653.6 Mn in 2025 and is expected to reach USD 3,911.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics:

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2021, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study:

• This report provides in-depth analysis of the global herpes simplex virus treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Detailed Segmentation:

• Global Herpes Simplex Virus Treatment Market, By Drug Type:
  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Other Drugs
• Global Herpes Simplex Virus Treatment Market, By Route of Administration:
  • Oral
  • Injection
  • Topical
• Global Herpes Simplex Virus Treatment Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Fresenius SE & Co. KgaA
  • Glenmark Pharmaceuticals
  • Carlsbad Tech
  • GlaxoSmithKline PLC
  • Zydus Cadila
  • Epi Health LLC
  • Viatris Inc.
  • Apotex Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in prevalence of infections of the herpes simplex virus
  • Social stigma about sexually transmitted diseases (STDs)
  • Increase in demand for safe and effective HSV therapeutics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Herpes Simplex Virus Treatment Market, By Drug Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Acyclovir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Valacyclovir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Famciclovir
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Other Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

5. Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Injection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Herpes Simplex Virus Treatment Market, By Geography, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)

7. Competitive Landscape

• Fresenius SE & Co. KgaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Glenmark Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Carlsbad Tech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zydus Cadila
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Epi Health LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Apotex Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us